tbuckley/cabot-search huggingface dataset:
Impact of triggered palliative care consultation approaches on palliative care consult implementation in inpatient oncology.
Authors: Lisa Dimartino, Bryan J Weiner, Laura C Hanson, Morris Weinberger, Sarah Birken, Katherine Elizabeth Reeder-Hayes, Justin G Trogdon
Journal: Journal of Clinical Oncology (2017)

95 Background: Studies show palliative care (PC) delivered concurrently with cancer treatment improves outcomes, yet integration of PC with inpatient oncology is lacking. A promising approach to improve integration is a triggered palliative care consultation (TPCC), which is primarily based on clinical criteria (e.g. metastatic disease) and may include multiple strategies to support its use. This study evaluated the impact of two TPCC approaches on PC consult implementation (uptake and timeliness) in the solid tumor medical (MED) and gynecologic oncology (GYN) services at an academic medical center. Methods: MED TPCC used multiple strategies (chart review to identify eligible patients, training, clinician prompting); GYN TPCC used a single strategy (written guideline of clinical criteria for initiating a consult). PC consult information was obtained from medical charts and linked to all hospital encounter data for MED and GYN. The timeframe was 2010-2016 with TPCC onset in 2014 (GYN) and 2015 (MED). We compared PC consult implementation in GYN (single strategy) vs no strategy and MED (multiple strategies) vs GYN (single strategy). Difference-in-differences and modified Poisson regression was used to evaluate whether PC consult implementation differed after initiating strategies, adjusting for patient demographic and clinical characteristics. Results: Our sample included 5,873 MED and 3,889 GYN hospitalizations. Overall 8.8% of MED and 11.0% of GYN hospitalizations involved a PC consult. In regression analyses, use of a single strategy was associated with increased PC consult uptake vs no strategy (aRR: 1.45, p &lt; .05), while use of multiple strategies was associated with increased PC consult uptake vs use of a single strategy (aRR: 2.34, p &lt; .001). Across all comparisons, the strategies did not significantly impact PC consult timeliness. Conclusions: This study compared PC consult implementation across two inpatient oncology services and found a TPCC approach supported by multiple strategies had the greatest impact on uptake. Questions remain regarding which TPCC approach can most effectively achieve sustainability of uptake and PC consult timeliness in inpatient settings.
Noninvasive breast cancer orbital metastases treatment saving the visual and oculomotor nerves
Authors: H. Rudnicka, A. Jagiello-Gruszfeld, S. Jaczewska, I. Glogowska, I. Lemanska, T. Pienkowski
Journal: Journal of Clinical Oncology (2004)

786 Background: Orbital metastases in breast cancer patients (pts) are not common. Local treatment of this site (surgery, radiotherapy) is hazardous and with a high risk of permanent loss of vision. Systemic treatment (chemoterapy and hormonotherapy) appears to be optional in this group.Methods: 12 pts treated in our clinic from January 1998 to December 2003, aged from 33 to 73 years, (median 59), with metastatic lesions in the orbital region were analyzed. In 4 patients the orbital metastases were the first metastases observed and in the next 8 patients they were successive to other already treated with chemotherapy (2 pts due to liver and bone metastases, 2 pts due to skin metastases) and with hormonotherapy because of metastatic lesions in bones (4 pts). At the beginning of the treatment vision disorders and pain of the eyeball where observed in all pts. Three pts were treated with doxorubicin and cyclophosphamide, 3 pts with doxorubicin and docetaxel, 2 pts received the NF program (previously treated with anthracyclines), 1 patient cisplatin (as a third line chemotherapy), 1 capecytabine, 1 trastuzumab plus VNR and 1 patient with antiestrogen. Treatment was monitored with MRI and clinical examination. Results: A complete remission of orbital lesions was observed in 4 pts and a partial remission in 3 pts. The rest of the patients achieved stabilization of disease but in all cases vision disorders completely or partially disappeared. There was no recurrence of the metastatic diseases in the orbital region. Conclusions: Systemic treatment seems to be the optimal therapy in this group of pts, providing clinical benefit, after which we observed improvement of vision and no iatrogenic injuries of the visual and oculomotor nerves. No significant financial relationships to disclose.
An Alternate, Egg-Free Radiolabeled Meal Formulation for Gastric-Emptying Scintigraphy
Authors: Philippe Garrigue, Aurore Bodin-Hullin, Sandra Gonzalez, Quentin Sala, Benjamin Guillet
Journal: Clinical Nuclear Medicine (2017)

Tc-radiolabeled scrambled eggs (SEs) are most often used as the ingested solid phase for gastric-emptying scintigraphy, leading egg-reluctant patients to avoid the examination. We formulated and validated 2 egg-free alternate meals, in the absence of any commercialized formulation: chocolate mug cake (MC) and scrambled tofu (ST). Six healthy volunteers underwent gastric-emptying scintigraphy after ingesting Tc-radiolabeled MC, ST, or SE. Gastric retention indexes did not change significantly between formulations (% of overtime variation to SE: MC 7.75% ± 7.1%, ST 7.17% ± 5.8%; P = 0.6618, not statistically significant), suggesting MC and ST as interesting egg-free alternatives.
Male breast cancer: Clinico-pathological study with evaluation of biologic markers
Authors: D. Gupta, G. H. Perkins, S. M. Garcia, A. A. Sahin, L. P. Middleton
Journal: Journal of Clinical Oncology (2004)

777 Background: In contrast with female breast cancer, there is limited data on the expression of biologic markers and significance of clinicopathologic features in male breast cancer. Methods: We reviewed pathology and clinical data for 33 evaluable patients with MBC from 1981–1999. Immunohistochemical staining for ER, PR, AR, and cyclin D1 was performed. Results: Mean patient age was 61 years (range 35–80). 70% were Caucasian, 18% Hispanic, 12% African-American. 27% had a family history of breast/ovarian cancer in first-degree relatives. Patients presented as follows: with gynecomastia (33%), with a painless mass (33%), with nipple inversion/discharge (27%). Mean tumor size was 1.7 cm (range 0.1– 5.0 cm). The tumor was retroareolar/central in 67% patients. 88% had invasive ductal carcinoma while 12% had intracystic papillary DCIS. Tumor grade was as follows: high-grade (15), intermediate-grade (17), and low-grade (1). 40% had lymphovascular invasion, 15% presented with dermal involvement, and 12% had nipple involvement. Regarding evaluable biological markers: 86% were ER+, 75% PR+, 89% AR+, 67% cyclin D1+. OS was 85% (FU range 15–240 months), DFS was 64%. Overall survival and disease free survival for each biomarker is provided in the table below. Conclusions: The majority of tumors highly expressed ER, PR, AR, and cyclin D1, which may have important therapeutic implications for patients with male breast cancer. Patients with tumors that did not express AR and cyclin D1 performed poorly. Larger future studies will hopefully help to elucidate the prognostic implications of hormone receptor and cell cycle regulator expression in this population. No significant financial relationships to disclose.
Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN).
Authors: Enric Carcereny Costa, Anna Estival, Laia VilÃ Martinez, Maria de los Llanos GIL Gil Moreno, Teresa Moran, Beatriz Gutierrez, Eli Nancy Perez, Yolanda Luis, Josep Jove, Cristina Buges, Vanesa Quiroga, Jose Luis Cuadra-Urteaga, Sara Cros, Max Hardy-Werbin, Iris Teruel, Sara Ahlal, Nuria Pardo, Alberto Indacochea, Laia Capdevila, Rafael Rosell
Journal: Journal of Clinical Oncology (2015)

e22139 Background: During the last years, new predictive and less frequent biomarkers have emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) and BRAF mutations (BRAFm). We analyze retrospectively the frequency, clinical and tumor characteristics of NSCLC p TN( EGFR, KRAS and ALK wild-type). Methods: The study included data from all consecutive non-squamous and non-smokers squamous TN advanced NSCLC p diagnosed at our hospital from December 2008 to July 2014. Results: 101 p were included. The table below summarizes p characteristics. ROS1t were found in 4.9% p and were found more in female gender (100%), non-smokers(100%), stage IV (100%), adenocarcinoma histology (100%) and p had more lung metastasis(50% vs 34.2%), brain metastasis (50%vs 38.5%) and pleural/pericardial effusions (50% vs 12.8%). HER2m was found in 1 p (1.25%). Female, non-smoker and adenocarcinoma histology. BRAFm were found in 2 p ( 3.2%), one male and one female, smokers and adenocarcinoma histology. Valid results range from 85.6% to 96.2% for biopsy samples and from 78.2% to 81.4% for citology samples. Conclusions: ROS1t, HER2m and BRAFm have emerged as targetable oncogenic drivers in NSCLC. Although the prevalence is low (1%–2%), could be increased selecting by clinical and molecular characteristics. Citology samples could be useful to detect these molecular alterations. TOTAL(N101) ROS1(N81) BRAF(N80) HER2(N80) Mean age 61 58 63 63 Gender Male Female 65(64,3%) 36(35,6%) 57(70,3%) 24(29,6%) 52 (65%) 28(35%) 52(65%) 28(35%) Smoking history Current Former Never 38(37,6%) 41(40,5%) 22(21,7%) 32(39,5%) 37(45,6%) 12(14,8%) 33(41,2%) 31(38,7%) 16(20%) 33(41,2%) 31(38,7%) 16(20%) Histology Adenocarcinoma Squamous NOS LCC 88(87,1%) 5(4,9%) 6(5,9%) 2(1,9%) 72(88,8%) 3(3,7%) 6(7,4%) 0 71(88,7%) 2(2,5%) 5(6,2%) 2(2,5%) 71(88,7%) 2(2,5%) 5(6,2%) 2(2,5%) Sample type CItology Biopsy 29 (28,7%) 72 (71,2%) 27 (33,3%) 54 (66,6%) 23 (28,7%) 57 (71,2%) 23 (28,7%) 57 (71,2%) Site of metastasis Lung Bone Brain Liver 33 (32,6%) 28 (27,7%) 30 (29,7%) 9 (8,9% 28 (34,5%) 21 (25,9%) 25 (30,8%) 5 (6,1%) 25 (31,2%) 22 (27,5%) 27 (33,7%) 7 (8,7%) 25 (31,2%) 22 (27,5%) 27 (33,7%) 7 (8,7%)
A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
Authors: C. Conrad, H. Friedman, D. Reardon, J. Provenzale, E. Jackson, H. Serajuddin, D. Laurent, B. Chen, W. K. A. Yung
Journal: Journal of Clinical Oncology (2004)

1512
Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution
Authors: Karen Y. Kuo, Prag Batra, Hyunje G. Cho, Shufeng Li, Harvind S. Chahal, Kerri E. Rieger, Jean Y. Tang, Kavita Y. Sarin
Journal: Journal of the American Academy of Dermatology (2017)
Assessment of a Tele-education System to Enhance Retinopathy of Prematurity Training by International Ophthalmologists-in-Training in Mexico
Authors: Samir N. Patel, Maria Ana Martinez-Castellanos, David Berrones-Medina, Ryan Swan, Michael C. Ryan, Karyn E. Jonas, Susan Ostmo, J. Peter Campbell, Michael F. Chiang, R.V. Paul Chan, R.V. Paul Chan, Karyn E. Jonas, Michael F. Chiang, Susan Ostmo, J. Peter Campbell, Vivien Yap, Alexander D. Port, Samir N. Patel, Leslie D. Mackeen, Maria Ana Martinez-Castellanos, Samantha Salinas-Longoria, Rafael Romero, Andrea Arriola, Wei-Chi Wu, Rachelle Go Ang Sam Anzures, Camila V. Ventura, Michael F. Chiang, Susan Ostmo, Kemal Sonmez, Sang Jin Kim, J. Peter Campbell, R.V. Paul Chan, Karyn Jonas, Anton Orlin, Jason Horowitz, Osode Coki, Cheryl-Ann Eccles, Leora Sarna, Audina Berrocal, Catherin Negron, Kimberly Denser, Kristi Cumming, Tammy Osentoski, Tammy Check, Mary Zajechowski, Thomas Lee, Evan Kruger, Kathryn McGovern, Charles Simmons, Raghu Murthy, Sharon Galvis, Jerome Rotter, Ida Chen, Xiaohui Li, Kent Taylor, Kaye Roll, Jayashree Kalpathy-Cramer, Deniz Erdogmus, Stratis Ionnidis, Maria Ana Martinez-Castellanos, Samantha Salinas-Longoria, Rafael Romero, Andrea Arriola, Francisco Olguin-Manriquez, Miroslava Meraz-Gutierrez, Carlos M. Dulanto-Reinoso, Cristina Montero-Mendoza
Journal: Ophthalmology (2017)
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
Authors: Jesus García-Donas, Albert Font, Begoña Pérez-Valderrama, José Antonio Virizuela, Miquel Ángel Climent, Susana Hernando-Polo, José Ángel Arranz, Maria del Mar Llorente, Nuria Lainez, José Carlos Villa-Guzmán, Begoña Mellado, Aránzazu González del Alba, Daniel Castellano, Enrique Gallardo, Urbano Anido, Xavier García del Muro, Montserrat Domènech, Javier Puente, Rafael Morales-Barrera, Jose Luis Pérez-Gracia, Joaquim Bellmunt
Journal: The Lancet Oncology (2017)
Is prostate-specific antigen a surrogate for survival in advanced prostate cancer?
Authors: L. Collette, T. Burzykowski, K. Carroll, D. Newling, T. Morris, F. Schroder
Journal: Journal of Clinical Oncology (2004)

4551 Background: Surrogate endpoints are needed to shorten the duration of Phase III clinical trials in advanced prostate cancer. Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer. This study attempts to validate PSA endpoints as surrogates for overall survival (OS). Methods: Individual data from 2161 patients with advanced prostate cancer treated in studies comparing bicalutamide (‘Casodex’), either as monotherapy or in combination with an LHRHa, with castration were used in a meta-analytical approach to surrogate endpoint validation. PSA response, several definitions of time to PSA progression and longitudinal PSA measurements were considered. Results: The analyses confirmed the known association between the PSA endpoints and OS at the individual patient level (biomarker association). However, when comparing patients treated with bicalutamide-based treatment or castration, the effect of hormonal intervention on the PSA endpoint did not predict the effect on OS with a high degree of precision. The association between intervention on any PSA endpoint and OS, measured by the determination coefficient R2 (ranging from 0.10–0.66 for PSA progression, to 0.69 for the whole PSA profile) was generally low. Conclusions: It is a common misconception that a correlation at the individual level between PSA and OS is enough to demonstrate surrogacy. To demonstrate true surrogacy, a high correlation between the treatment effect on the surrogate and the treatment effect on the true endpoint needs to be established across groups of patients treated with two alternative interventions. The level of association observed in this study between the treatment effect on PSA endpoints and that observed on OS was in general low, showing that in Phase III clinical trials of hormonal treatments in advanced prostate cancer, treatment effects on OS cannot be predicted from observed treatment effects on PSA endpoints with a high degree of precision. This study indicates that PSA is unlikely to be a useful surrogate for OS in advanced prostate cancer. ‘Casodex’ is a trademark of the AstraZeneca group of companies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca AstraZeneca AstraZeneca AstraZeneca
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Authors: Angélique Vienot, Guillaume Beinse, Christophe Louvet, Louis de Mestier, Aurélia Meurisse, Francine Fein, Bruno Heyd, Denis Cleau, Christelle d’Engremont, Anne-Claire Dupont-Gossart, Zaher Lakkis, Christophe Tournigand, Olivier Bouché, Benoît Rousseau, Cindy Neuzillet, Franck Bonnetain, Christophe Borg, Dewi Vernerey
Journal: JNCI Journal of the National Cancer Institute (2017)

In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line chemotherapy (L2). Better discrimination of overall survival (OS) may help clinical decision-making. We aimed to predict OS from the beginning of L2 and to assess the benefit from chemotherapy among the identified risk groups.Analyses were derived from all consecutive aPDAC patients treated at Besancon University Hospital, Besancon, France, between January 2003 and December 2013 (n = 462). The association of 50 parameters with OS was evaluated using univariate and multivariable Cox analyses. Based on the final model, a prognostic nomogram and score were developed and externally validated. Patients in the external validation cohort who received L2 (n = 163) were treated at three French institutions between January 2010 and April 2016. All statistical tests were two-sided.In the development cohort, 395 patients (85.5%) were eligible for L2, of which 261 (66.1%) were treated. Age, smoking status, liver metastases, performance status, pain, jaundice, ascites, duration of first-line, and type of L2 regimen were identified as independent prognostic factors for OS in L2. The score determined three groups with median OS of 11.3 months (95% confidence interval [CI] = 9.1 to 12.9 months), 3.6 months (95% CI = 2.6 to 4.7 months), and 1.4 months (95% CI = 1.2 to 1.7 months), for low-, intermediate-, and high-risk groups, respectively ( P < .001). By applying the score in the population eligible for L2 but untreated, the chemotherapy benefit was statistically significant across all groups, but with a magnitude of the effect decreased statistically significantly from low- to high-risk groups ( P = .001 for treatment and risk groups interaction term). The ability of the score to discriminate OS was confirmed in the external validation cohort.This prognostic nomogram and score in patients with aPDAC can accurately predict OS before administration of L2 and may help clinicians in their therapeutic decisions.
The leukotriene B4–leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury by modulating neutrophil recruitment
Authors: Bo Deng, Yuli Lin, Shuai Ma, Yin Zheng, Xuguang Yang, Bingji Li, Wenyan Yu, Qingqing Xu, Tingyan Liu, Chuanming Hao, Rui He, Feng Ding
Journal: Kidney International (2017)
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
Authors: Emma Beddowes, James Spicer, Pui Ying Chan, Ramsay Khadeir, Javier Garcia Corbacho, Dimitra Repana, Jeremy P. Steele, Peter Schmid, Teresa Szyszko, Gary Cook, Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Michael Sheaff, Bor-Wen Wu, John Bomalaski, Simon Pacey, Peter W. Szlosarek
Journal: Journal of Clinical Oncology (2017)

Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non–small-cell lung cancer (NSCLC). Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naïve patients (five MPM, four NSCLC) received weekly ADI-PEG 20 doses of 18 mg/m 2 , 27 mg/m 2 , or 36 mg/m 2 , together with pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2 which were given every three weeks (maximum of six cycles). Patients achieving stable disease or better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal. Adverse events were assessed by Common Terminology Criteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for NSCLC and by modified RECIST criteria for MPM. Results No dose-limiting toxicities were reported; nine of 38 reported adverse events (all grade 1 or 2) were related to ADI-PEG 20. Circulating arginine concentrations declined rapidly, and citrulline levels increased; both changes persisted at 18 weeks. Partial responses were observed in seven of nine patients (78%), including three with either sarcomatoid or biphasic MPM. Conclusion Target engagement with depletion of arginine was maintained throughout treatment with no dose-limiting toxicities. In this biomarker-selected group of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-prognosis tumors. Therefore, we recommend a dose for future studies of weekly ADI-PEG 20 36 mg/m 2 plus three-weekly cisplatin 75 mg/m 2 and pemetrexed 500 mg/m 2 .
Pap test and a new biomarker-based technology for enhancing the visibility of abnormal cells
Authors: N. S. Markovic, O. Markovic, J. Sundeen, W. Smith, S. N. Markovic
Journal: Journal of Clinical Oncology (2004)

9561 Background: At ASCO 2001, we introduced the Cervical Acid Phosphatase - Papanicolaou (CAP-PAP) test as a new, biomarker-driven technology for detection of abnormal cervical cells on Pap smears. Since this report, we conducted two clinical trials to assess the value of this test for cervical cancer screening in general (N=1,500) and a high-risk population (N=500). This technology is commercially available as the MarkPap™ Research Kit (BioSciCon, Inc., Rockville, MD, USA). Methods: Multicenter, random assignment, assessors blinded, split sample, concurrent control 3-group (test and two controls [Pap smears and ThinPrep thin layers] clinical trial was conducted on 1,500 specimens obtained from eligible subjects coming for regular Pap test. Specimens collected in PreservCyt and transferred onto microscopic slides using the ThinPrep Processor 2000 were split in two samples before processing. Specimens obtained with cervical epithelium abrading devices, were split by the physician in two samples (smears). Primary efficacy endpoints were the portion of detected abnormal samples and the portion of false negative readings. Accuracy was measured against a cytology standard (association or adjudication). Results: * δ= 30% of Ps (performance of the standard control group). MPT= CAP-PAP test. ThP= ThinPrep Pap test. Pap=Pap smears. Pe= performance of the test group (experimental) Conclusion: This data suggests that the new technology is more sensitive (with equivalent specificity) than either conventional Pap smear or ThinPrep Pap test. However, when specimens were collected in PreservCyt, due to alcohol inhibition of the enzyme, this sensitivity was reduced. This work was supported in part by NCI, NIH, via SBIR Phase-1 and Phase-2 grants: 1 R43CA086767–01, and 2-R44CA086767–02. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration BioSciCon, Inc. BioSciCon, Inc. BioSciCon, Inc. NIH (# 1R43CA86767 –01) NCI (2RCA086767–02) BioSciCon, Inc.